Home › NCT06805461
PumaRx Registry Trial
A Multi-Center, Observational, Post-Marketing, Registry Study Following Patients With Solid Tumors Treated With Therapeutic Agents Via Localized Intra-Arterial Delivery Using the RenovoCath® Catheter
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Eligibility Criteria: 1. Male and female patients who have been diagnosed with solid tumor cancers and are at least 18 years of age at the time of the first IA procedure 2. Patients willing to provide informed consent and HIPAA release for use of their relevant medical records
About the study
This study is a multicenter, observational, post-marketing, registry study designed to track the safety and performance of the RenovoCath® device and assess survival outcomes in patients diagnosed with solid tumors who are treated with localized intra-arterial (IA) delivery of therapeutic agents to solid tumors using the RenovoCath® catheter.
What is being tested
- RenovoCath® (device)
Sponsor: RenovoRx · Participants: 1,000 · Started: Aug 1, 2025
Contact the study team
- Leesa M Gentry · Phone: 650-284-4433
- Nicolette G Keller · Phone: 650-284-4433
Official record on ClinicalTrials.gov — NCT06805461
Locations in the U.S.
| Florida | Baptist Health South Florida, Coral Gables |
| Pennsylvania | University of Pennsylvania Medical Center, Pittsburgh |
| Vermont | The University of Vermont Medical Center, Burlington |
From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.